Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance

Yawen Zhang, Xiangle Zeng, Hairong Wang, Ranran Fan, Yike Hu, Xuejie Hu and Jianchun Li

School of Pharmacy, Bengbu Medical College, Bengbu, China

ABSTRACT
Multidrug resistance (MDR) and lack of targeting specificity are the main reasons why traditional drug therapies fail and produce toxic side effects in cancer chemotherapy. In order to increase targeting specificity and maximize therapeutic efficacy, new intelligent drug delivery systems are needed. In this study, we prepared the hyaluronic acid (HA) conjugated dasatinib (DAS) and D-α-tocopherol acid polyethylene glycol succinate (TPGS) copolymer nanoparticles (THD-NPs). The water solubility of the hydrophobic drug DAS was improved by chemically linking with HA. HA can bind to the over-expressed CD44 protein of tumor cells to increase targeting specificity. TPGS can inhibit the activity of P-glycoprotein (P-gp), and increase the intracellular accumulation of drugs. The prepared drug-loaded nanoparticle has a particle size of 82.23 ± 1.07 nm with good in vitro stability. Our in vitro studies showed that THD-NPs can be released more rapidly in a weakly acidic environment (pH = 5.5) than in a normal physiological environment (pH = 7.4), which can realize the selective release of nanoparticles in tumor cells. Compared to free drugs, THD-NPs showed more efficient cellular uptake, effectively increased the cytotoxic effect of DAS on nasopharyngeal carcinoma HNE1 cells drug resistance HNE1/DDP cells and increased the accumulation of drugs in HNE1/DDP cells, which may be due to the inhibitory effect of TPGS on the efflux function of P-gp. In vivo experiments showed that THD-NPs can effectively inhibit tumor growth without obvious side effects. In conclusion, the targeted and pH-sensitive nanosystem, we designed has great potential to overcome drug resistance and increase therapeutic effects in cancer treatment.

Introduction
Dasatinib (DAS) is a second-generation tyrosine kinase inhibitor. As a multitarget small molecule drug, it can target a variety of tyrosine kinases related to tumor cell growth. The most sensitive targets include BCR-ABL, SRC family, receptor tyrosine kinases (c-KIT, PDGFR, DDR1), and TEC family kinases, etc (Montero et al., 2011; Lindauer & Hochhaus, 2018). As the first-line drug for chronic myelogenous leukemia (Levêque et al., 2020), DAS is 300 times stronger than imatinib in inhibiting BCR/ABL activity (Lindauer & Hochhaus, 2010). Recent studies have found that the drug can inhibit cancer cell replication, migration, invasion, and trigger tumor cell apoptosis (Lindauer & Hochhaus, 2018). It has shown obvious therapeutic effects in a variety of solid tumors, and research on breast cancer has entered Clinical Trials. However, DAS has poor water solubility, absorbs easily affected by the pH, and its terminal half-life is only 3–4 h (Horinkova et al., 2019). At the same time, there are a series of side effects (Niza et al., 2019). Therefore, it is necessary to design a suitable drug carrier, in order to achieve safe and efficient delivery of DAS, improve its efficacy and reduce adverse reactions.

In addition to the development of new targets for modern antitumor drug therapy, the development of new drug delivery systems is also particularly important. With the development of nanometer medicine, Nano Drug Delivery System (NDDS) has shown superior performance (Ren et al., 2021; Tian et al., 2021; Zhang et al., 2021; Zhou et al., 2021). Through different modifications to the NDDS carrier, can make its active targeting and environmental responsiveness (Zhang et al., 2021; Zhou et al., 2021). As a type I transmembrane glycoprotein, CD44 protein is widely expressed in endothelial cells, mesenchymal cells, and mesoderm-derived cells. It can promote dynamic interactions inside and outside cells, cell movement, and transfer. Because of its abnormal expression in tumor cells, it is often used as a tumor treatment target to prepare active targeting agents (Tian et al., 2017). As a natural polysaccharide, hyaluronic acid (HA) is one of the main CD44 ligands. The specific binding of HA to CD44 can make HA-based nanodrug delivery system localize and concentrate on tumor sites. At the same time, HA has excellent biocompatibility, hydrophilicity, low immunogenicity, chemical modifiability, and biodegradability, making it an ideal material for targeted drug delivery systems (Williams et al., 2019).
Multidrug resistance (MDR) is one of the main obstacles to effective chemotherapy of tumor. Mechanisms of MDR production include increased efflux of drugs to reduce intracellular accumulation of drugs, promoting antiapoptotic mechanisms, and repairing DNA damage (Almalik et al., 2013; Koshkin et al., 2013; Singh et al., 2017; Trujillo-Nolasco et al., 2019). Among them, P-glycoprotein (P-gp), as a membrane transporter of the ATP binding cassette family, can pump out substrate drugs through an ATP-dependent mechanism, thereby reducing intracellular drug accumulation, which is one of the main causes of MDR (Chen et al., 2016; Gupta et al., 2017; Li et al., 2017). A variety of P-gp inhibitors such as Pluronic, Verapamil, and TPGS have been discovered (Gottesman et al., 2002; Negi et al., 2019; Xu et al., 2020). Among them, D-α-tocopherol acid polyethylene glycolsuccinate (TPGS), an amphiphilic structure, can self-assemble to form nanoparticles and improve the permeability to cancer cells, making it an ideal nanocarrier (Wang et al., 2016; Popova et al., 2019; Tao et al., 2020).

In this study, we designed to link the hydroxyl group of DAS and the carboxyl group of HA through ester construction to obtain an amphiphilic complex with DAS as the hydrophobic segment and HA as the hydrophilic segment. HA acts as a ligand for CD44 protein, which can target tumor cells overexpressing CD44 receptor, thus enabling targeted drug delivery (Gao et al., 2019). At the same time, the addition of TPGS to the carrier increases the stability of the nanoparticles, inhibits the P-gp activity, and increases the intracellular accumulation of the drug. Due to the abnormal metabolism of tumor cells, the pH of tumor tissues is lower than that of normal tissues (Wan et al., 2020), and the ester in DAS-HA complex can be broken in response to the weak acidic microenvironment in tumor cells, thereby releasing the drug. Briefly, this experiment proposes to design a pH-sensitive targeted nanoparticle to achieve the targeted release of DAS, and increase its intracellular accumulation, to provide a safe and efficient agent for DAS (Figure 1).

**Materials and methods**

**Chemicals**

DAS and TPGS were from Macklin Biochemical Technology Co. Ltd. (Shanghai, China), and HA (MWCO: 8814 Da) was provided by Bloomage Biotechnology Corporation Limited (Shandong, China). EDC and DMAP were purchased from Aladdin Co. Ltd. (Shanghai, China). HA-DAS complex was prepared by the research group, phosphate-buffered saline (PBS) obtained from Saiguo Biotechnology Co. Ltd.

**Figure 1.** The construction, in vivo release and mechanism of THD-NPs. THD-NPs enter the systemic blood circulation through intraperitoneal injection. The CD44 receptor overexpressed on the surface of tumor cells specifically binds to the hyaluronic acid of THD-NPs, and the drug is transported into tumor cells through receptor-mediated endocytosis. THD-NPs disintegrate in response to low pH in tumor cells and release drugs. TPGS inhibits P-gp function to reduce drug efflux, increase intracellular accumulation of drugs, cause cancer cells to die and reduce toxicity to normal cells.
Hangzhou, China), Dialysis bags with a molecular weight cutoff of 3.5KDa (Viskase Companies, Inc., Darien, IL) were used. RPMI 1640 medium was acquired from Thermo Fisher Biochemical Products (Beijing, China). Fetal bovine serum was supplied by Tian Hang Biotechnology Co. Ltd. (Hangzhou, China). HNE1/DDP cell line and HNE1 cell line was purchased from Beijing Beina Chuanglian Biotechnology Research Institute, and was cultured and stored in the Laboratory of Biochemistry and Pharmacology, Bengbu Medical College.

**Cell culture and animals**

HNE1 cells were cultured in RPMI 1640 medium containing 1% penicillin and streptomycin, 10% fetal bovine serum at 37°C and 5% CO2 in humidified incubator. HNE1/DDP cells were cultured in RPMI 1640 medium containing 1% penicillin and streptomycin, 1 μg/mL cisplatin, 10% fetal bovine serum at 37°C and 5% CO2 in humidified incubator. BALB/C nude mice was obtained from Cavens lab animal company (Jiangsu, China), and raised in a laboratory without a specific pathogen barrier.

All animal procedures comply with animal ethics requirements. The animal experimental procedure was approved by the Animal Care Committee of Bengbu Medical College (License No.: 2018033) on 19 January 2018 and conformed to the Animal Ethical Standards and Use Committee at Bengbu Medical College.

**Preparation and characterization of self-assembly nanoparticle**

The connection of DAS and hyaluronic acid (HA-DAS) referred to the previous preparation method of the research group. In short, in the presence of the catalysts EDC and DMAP, the carboxyl group of HA is linked to the hydroxyl group of DAS.

In order to synthesize HA-DAS/TPGS mixed micella (THD-NPs), the thin films of polymer and TPGS were first established, and then the thin films were hydrated (Cheng et al., 2018). During the preparation, a total of 20 mg HA-DAS and TPGS were taken and dissolved with water and methanol. After ultrasonication in an ice bath for 30 min, the solvent was removed using a rotary evaporator at 35°C. The micelle solution was obtained by dispersing the film with water and filtering it through a 0.22 μm filtration membrane (Figure 2).

Zeta Sizer Nano series Nano-ZS (Malvern Instruments Ltd., Malvern, UK) was used to evaluate the THD-NPs size distribution. Characterization of THD-NPs particle morphology was performed using transmission electron microscopy (TEM).

**Evaluation of drug loading**

The ester structure was broken by a strong base hydrolysis method to determine the DAS content. The mixture of 1 mL micelle solution and 100 μL NaOH solution (1 mol/L) was fully reacted for 30 min, then 100 μL of HCl solution (1 mol/L) was added to neutralize the solution. Finally, 1 mL methanol was added for ultrasonic demulsification at 200 W power for 5 min. From this, the DAS concentration was determined by HPLC. The drug loading was calculated based on Equation (1)

\[
DL\% = \frac{W_1}{W} \times 100\%
\]

where:

- \( W_1 \): mass of drug in micelle
- \( W \): mass of the mixed micelle

**Characterization of the stability of THD-NPs**

The THD-NPs were incubated with 10% fetal bovine serum (FBS)/PBS (pH 7.4) at room temperature and sampled at set time points, then the size distribution was evaluated by Zeta Sizer Nano Series Nano-ZS to investigate the stability of THD-NPs in vitro.

**Evaluation of in vitro drug release kinetics**

In order to evaluate the feasibility of THD-NPs release in vivo, PBS of different pH were used to simulate the normal physiological environment (pH = 7.4) and tumor microenvironment (pH = 5.5), and the drug release profile of THD-NPs was determined by dialysis (Priya et al., 2021). Briefly, THD-NPs (3 mL) were added to dialysis bags (MWCO: 3.5 KDa) and placed in PBS with different pH values. The PBS (1 mL) was withdrawn at different time interval and replenish the same Volume of PBS. The content of DAS in each dialysate was measured by HPLC.

**In vitro cellular uptake of nanoparticles and DAS accumulation**

HNE1/DDP cells (1 x 10^5 cells/well) were inoculated into a six-well plate and cultured overnight. After incubation with coumarin-6, TPGS loaded with coumarin-6 (TC-NPs) and
TPGS/HA-DAS loaded with coumarin-6 (THDC-NPs) at 37°C and 5% CO₂ for 2 h, the cells were washed with PBS solution, fixed with 4% paraformaldehyde for 15 min, and stained with DAPI for 10 min. Observe with fluorescence microscope.

HNE1/DDP cells (5 × 10³ cells/well) were seeded in 24-well plates and incubated with THD-NPs and HD-NPs at 37°C for 1, 2, and 4 h, respectively, at a concentration of 50 μM (as DAS content). The cells were centrifuged at 4°C, and 200 μL of cell lysate was added to the lower precipitate and incubated in an ice bath for 30 min. The supernatant was removed by centrifugation again at 14,000 rpm for 10 min at 4°C, and the supernatant was used for protein quantification. Finally, the supernatant (100 μL) was mixed with methanol (300 μL) by ultrasonic extraction, centrifuged at 5000 rpm for 10 min, and the supernatant was collected for DAS concentration determination by HPLC. The drug concentration per unit of protein was determined (Bhattacharya et al., 2020).

**Vitro verification of anticancer activity of nanoparticles**

The MTT method was used to examine the in vitro cytotoxicity of THD-NPs. HNE1 and HNE1/DDP cells in the logarithmic growth phase were seeded in a 96-well plate at a density of 5 × 10³ cells/well for 24 h, then the cell culture medium was replaced with 100 μL medicated medium containing different concentrations of DAS and THD-NPs. After 24 and 48 h of incubation, added 20 μL of MTT (5 mg/mL in PBS) to each well, removed the solution after incubating for 4 h, and added 200 μL of DMSO, measured the absorbance at 490 nm after incubated at 37°C for 30 min.

**Antitumor effects of nanoparticles in vivo**

To evaluate the antitumor effect of THD-NPs in vivo, we established a HNE1 solid tumor model, for that HNE1 cells (5 × 10⁶) were subcutaneously injected into the right upper limb of BALB/C nude mice. The tumor-bearing mice were randomly divided into three groups (control group, DAS group, THD-NPS group, n = 3/group). When the tumor volume grew to about 100 mm³, each group was intraperitoneally injected with the corresponding drug preparations every 2 days for 2 weeks. The body weight and tumor volume of the mice were recorded during the administration. After 2 weeks of continuous administration, the tumor tissues were extracted and weighed. To evaluate the biosafety of THD-NPS, organs such as heart, liver, lung, spleen, and kidney were extracted for HE staining.

**Statistical analysis**

All experimental values were expressed as mean ± SD and all experiments were performed independently and repeated at least three times. Statistical comparisons of data sets were evaluated using the one-way ANOVA analysis. p < .05 was considered statistically significant.

Figure 3. Size of THD-NPs. Dydromic size distribution of THD-NPs, different colors represent the results of three tests (n = 3).

Table 1. Average size and polydispersity index (PDI) of THD-NPs.

| Sample   | Size (nm) | PDI     |
|----------|-----------|---------|
| THD-NPs  | 82.23 ± 1.07 | 0.33 ± 0.004 |

The data represented as the mean ± SD (n = 3).

Figure 4. TEM characterization of THD-NPs. Scale bar = 1 μm.

**Results and discussion**

**Characterization**

Firstly, we characterized the physicochemical parameters of the THD-NPs. The proportion of HA-DAS and TPGS affects the particle size of the micelle. As the proportion of TPGS increases, the micelle particle size decreases gradually, while the drug load of DAS also decreases correspondingly. After comprehensive consideration, HA-DAS: TPGS is finally selected as 6:1. The results showed that the hydromechanical diameter of THD-NPs was 82.23 ± 1.07 nm and PDI was 0.33 ± 0.004 (Figure 3; Table 1). TEM maps show that THD-NPs are uniformly spherical (Figure 4).

After determining the optimal prescription, free DAS was released by destroying the ester compound, and the drug loading was determined by HPLC. The results showed that the drug loading was 2.1%.

The in vitro stability was investigated by 10% FBS/PBS (pH = 7.4). After 48 h of co-incubation, the particle size of THD-
NPs was changed to 85.21 ± 1.75 nm, and there was no significant change in the particle size at each time point compared to 0 h (Figure 5), which indicated that THD-NPs had good stability.

**Evaluation of pH-responsive release of THD-NPs in vitro**

THD-NPs was set for sustained release and pH-responsive release. When the characteristics and stability of THD-NPs were revealed, we need to verify the release of DAS. This is one of the main parameters of the carrier.

In PBS buffer with pH = 7.4, THD-NPs showed slow drug release within 24 h, with a cumulative release rate of 44.93%. In PBS buffer with pH = 5.5, the release rate of THD-NPs was accelerated compared to pH = 7.4, and the cumulative release rate reached 56.75% (Figure 6).

As we all know, the pH of human blood is about 7.4, and the tumor tissues have a low pH due to abnormal metabolism of tumor cells. The above data indicated that THD-NPs has pH responsiveness, so that after intravenous administration, THD-NPs will not release all the drugs prematurely in the blood, but after reaching the tumor tissues, it will accelerate the release of the drugs, thereby realizing the targeted delivery and release of drugs.

**Uptake of tumor cells in vitro**

We need to investigate whether THD-NPs can exert its targeting effect on cancer cells, thereby increasing the intracellular accumulation of nanoparticles. Since THD-NPs does not have fluorescence, the fluorescent substance coumarin-6 was selected, TPGS, and TPGS/HA-DAS containing coumarin-6 (TC-NPs, THDC-NPs) were prepared according to the preparation method of THD-NPs. Our research showed that almost no fluorescence was seen in cells treated with free coumarin-6. Intracellular fluorescence increased slightly after TC-NPs treatment, which may be due to EPR effect. THD-NPs group showed the highest fluorescence, which proved that the addition of HA in the nanoparticle carrier could effectively promote THD-NPs nanoparticles to target cancer cells (Figure 7).

**Intracellular accumulation of drugs**

After confirming that nanoparticles can target tumor cells, we further explored the amount of intracellular drug accumulation caused by nanoparticles. The mechanism of HNE1/DDP cell resistance to cisplatin includes increased drug efflux caused by P-gp (Du et al., 2018). TPGS has been proven to inhibit P-gp activity, thereby improving cell MDR. We added TPGS to the carrier in order to improve the stability of the nanoparticles on the one hand, and on the other hand we hope that it can increase the accumulation of drugs in the cell (Huo et al., 2017). Therefore, we prepared HD-NPs (HA-DAS) without TPGS according to the preparation method of THD-NPs. Incubated both nanoparticles with HNE1/DDP cells simultaneously to detect the intracellular drug content at different time points. The results are shown in Figure 8.

**Cytotoxic effect of THD-NPs on both HNE1 and HNE1/DDP cell lines**

In order to detect the antitumor activity of THD-NPs in vitro, HNE1 cell lines and cisplatin-resistant HNE1/DDP cell lines were selected. In previous studies, HNE1/DDP cell lines have been proved to be typical cisplatin-resistant cell lines, and drug resistance mechanisms include drug efflux caused by P-gp. The above experiments have proved that THD-NPs can increase the amount of intracellular drugs by inhibiting the function of P-gp, and we further studied the proliferation inhibitory effect of THD-NPs on the two cell lines. After the free drug and THD-NPs acting on the two cell lines for different periods of time, the MTT results showed that after 48 h of action, the IC₅₀ values of the free DAS on HNE1 and HNE1/DDP cell lines were 54.72 μM and 62.57 μM, respectively. After making it into nanoparticles, the IC₅₀ values of HNE1 and HNE1/DDP cell lines were reduced to 30.99 and 35.03 μM, respectively. It is suggested that THD-NPs have
more significant cytotoxic effects on the two cell lines (Figure 9; Table 2).

**Investigation of anti-tumor effect of nanoparticles in vitro**

Two weeks after the right upper limb of BALB/C nude mice was inoculated with HNE1 cells, the tumor volume reached about 100 mm$^3$, and the administration was started on the 12th day. Each nude mouse was injected with 200 µL of the different pharmaceutical preparation, and the dose was 5 mg/kg (calculated by DAS content). The results are shown in Figure 10.

The weight changes of mice in each group were similar (Figure 10(B)), suggesting that the two treatments had no significant effect on the growth of mice. Tumor growth curve is shown in Figure 10(A), the average tumor volume of the saline group increased from 104.84 to 1550.63 mm$^3$, while the DAS group and THD-NPS group grew from 100.29 and 86.35 mm$^3$ to 1094.85 and 760.24 mm$^3$, respectively. The results showed that after the mice were treated with free DAS and THD-NPS, compared with the saline group, both the DAS group and the THD-NPs group showed tumor suppression effect, and the antitumor effect of THD-NPs group was the most obvious (Figure 10(D)). The morphological appearance of the isolated tumor after the end of the administration also proved the above conclusion (Figure 10(C)). The results of HE staining of the tumor showed that compared with the control group, the cytoplasm of tumor cells in the DAS group disappeared, some of the nuclei were pyknotic, and inflammatory cells infiltrated. Large areas of necrosis and more apoptotic cells appeared in the THD-NPs group. It suggested that THD-NPs had significant tumor-suppressive effect. This result may be attributed to the active targeting effect produced by the specific binding of HA and CD44 protein and the passive targeting effect of nanoparticles through the EPR effect, thereby achieving targeted drug delivery and improving drug efficacy (Figure 11).

**Biosafety evaluation of THD-NPs**

For a new drug preparation, safety is one of the most important factors. After it has been confirmed that THD-NPs
have no significant effect on the body weight of mice during treatment, we need to evaluate the systemic toxicity caused by nanoparticles. Heart, liver, spleen, lung, and kidney tissues were sectioning, and histological morphology was observed by HE staining. Among them, the liver and kidney are the most important organs for drug metabolism. We focus on the liver and kidney toxicity caused by nanoparticles.

The pathological section results showed that, in the control group and THD-NPs group, the central hepatic vein was normal, and the hepatic cord was radial. In the DAS group, there was no obvious central vein, a large number of inflammatory cells were infiltrated, and some areas were necrotic. The glomeruli and tubules in the control group and THD-NPs group were normal, while the mesangial proliferation and sclerosis in the DAS group was accompanied by necrosis of tubule epithelial cells.

The above results showed that, compared with the control group, the DAS group had liver and kidney toxicity, and the THD-NPs group had a significant decrease in liver and kidney toxicity, which was similar to the control group. The results of other organs were the same as above. The above data all showed that the prepared THD-NPs had a protective effect on the hepatotoxicity of free drugs and had good biosafety.

**Conclusion**

In this study, we have successfully constructed a safe and efficient drug delivery system that can achieve a slow and sustained pH-responsive release of drug, target tumor tissue, and potentially reverse MDR. The nanosystem takes DAS as part of the carrier, effectively improving the lipid solubility of the drug. Cell uptake experiments confirmed that the specific binding of HA and CD44 achieved specific targeting effect on tumor cells. The results of the in vitro release experiment showed that when the nanoparticles entered tumor cells through receptor-mediated endocytosis, the ester bond was broken, DAS-HA was degraded, and the drug was released. The intracellular drug accumulation experiments proved that the addition of P-gp inhibitor (TPGS) increased the intracellular drug concentration of drug-resistant cells and effectively reversed the MDR of tumor cells. **In vitro** cytotoxicity assays
Figure 10. Evaluation of the anti-tumor effect of THD-NPs in vivo. (A) Tumor growth curve. Two weeks after inoculation with HNE1 cells, nude mice were injected intraperitoneally with equal amounts of saline, free DAS, and THD-NPs (5 mg/kg, calculated as DAS concentration), record the tumor weight and mouse body weight every 2 days during the administration period (B). (C) The tumor morphology of the mice in each group after the administration. (D) The tumor growth inhibition rate. The data are represented as the mean ± SD (n = 3). (E) H&E staining of the tumors after free DAS and THD-NPs treatment versus control. Scale bar = 50 μm.

Figure 11. H&E staining of the heart, liver, spleen, lung, and kidney after free DAS and THD-NPs treatment versus control. Histological sections of heart, liver, spleen, lung, and kidney from the nude mice were stained with hematoxylin and counter-stained with eosin and microscopically analyzed for histopathological examinations of tissue toxicity. The images were taken at 400× objective lenses. Scale bar = 50 μm.
and in vivo antitumor experiments demonstrated that THD-NPs exhibited superior antitumor effects compared with free DAS. In conclusion, our study shows that HA-modified TPGS hybrid micelles can serve as effective carriers for DAS-targeted drug delivery and reversal of MDR.

Acknowledgments

The authors thank Ms. Xiaojiang Guo for her help on proofreading this manuscript.

Author contributions

The experiments were designed and investigated by Y.Z. and H.W.; The experiments were performed by Y.Z., X.Z., H.W.; The data were analyzed by R.F., X.H., and Y.H.; The paper was written by Y.Z. and X.Z.; Project Administration and Supervision, J.L.

Disclosure statement

The authors declare no conflicts of interest.

Funding

This work was supported by the Key Program of Anhui University Natural Science Research [Grants, KJ2018A0998], Scientific Research Innovation Projects of Bengbu Medical College of Anhui Province [Grants, ByxCC20035], and Scientific Research Innovation Projects of Bengbu Medical College of Anhui Province [Grants, ByxCC1929].

References

Almalik A, Karimi S, Ouasti S, et al. (2013). Hyaluronic acid (HA) presentation as a tool to modulate and control the receptor-mediated uptake of HA-coated nanoparticles. Biomaterials 34:5369–80.

Bhattacharya S, Ghosh A, Maiti S, et al. (2020). Delivery of thymoquinone through hyaluronic acid-decorated mixed Pluronic® nanoparticles to attenuate angiogenesis and metastasis of triple-negative breast cancer. J Control Release 322:357–74.

Chen Z, Shi T, Zhang L, et al. (2016). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 370:153–64.

Cheng C, Meng Y, Zhang Z, et al. (2018). Tumoral acidic pH-responsive cis-diaminodichloro platinum-incorporated Cy5.5-PEG-g-A-NA nanoparticles for targeting delivery of CDDP against cervical cancer. ACS Appl Mater Interf 10:26682–92.

Du C, Qi Y, Zhang Y, et al. (2018). Epidermal growth factor receptor-targeting peptide nanoparticles simultaneously deliver gemcitabine and olaparib to treat pancreatic cancer with breast cancer 2 (BRCA2) mutation. ACS Nano 12:10785–96.

Gao J, Liu J, Xie F, et al. (2019). Co-delivery of docetaxel and salinomycin to target both breast cancer cells and stem cells by PLGA/TPGS nanoparticles. Int J Nanomed 14:9199–216.

Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58.

Gupta B, Ramasamy T, Poudel BK, et al. (2017). Development of bioactive PEGylated nanostructured platforms for sequential delivery of doxorubicin and imatinib to overcome drug resistance in metastatic tumors. ACS Appl Mater Interf 9:9280–90.

Horrínova J, Sima M, Stanar O. (2019). Pharmacokinetics of dasatinib. Prague Med Rep 120:52–63.

Huo Q, Zhu J, Niu Y, et al. (2017). pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer. Int J Nanomed 12:8631–47.

Karousou E, Misra S, Ghatak S, et al. (2017). Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol 59:3–22.

Koshkin V, Yang BB, Krylov SN. (2013). Kinetics of MDR transport in tumor-initiating cells. PLoS One 8:e79222.

Leveque D, Becker G, Bilger K, Natarajan-Amé S. (2020). Clinical pharmacokinetics and pharmacodynamics of dasatinib. Clin Pharmacokinet 59:849–56.

Li M, Jin S, Cao Y, et al. (2021). Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway. Cancer Cell Int 21:19.

Li Y, Xu X, Zhang X, et al. (2017). Tumor-specific multiple stimuli-activated dendrimeric nanosystems with metabolic blockade surmount chemotherapy resistance. ACS Nano 11:416–29.

Lindauer M, Hochhaus A. J. (2010). Dasatinib. Recent Results Cancer Res 184:83–102.

Lindauer M, Hochhaus A. J. (2018). Dasatinib. Recent Results Cancer Res 212:29–68.

Montero JC, Seoane S, Ocana A, et al. (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17:5546–52.

Negi LM, Talegaonkar S, Jaggi M, et al. (2019). Hyaluronated imatinib liposomes with hybrid approach to target CD44 and P-gp overexpressing MDR cancer: an in-vitro, in-vivo and mechanistic investigation. J Drug Target 27:183–92.

Niza E, Nieto-Jimenez C, Noblejas Lopez M. (2019). Poly(cyclohexene phthalate) nanoparticles for controlled dasatinib delivery in breast cancer therapy. Nanomaterials (Basel) 9:1208.

Popova M, Mishaylova R, Momokov G, et al. (2019). Verapamil delivery systems on the basis of mesoporous ZSM-5/KIT-6 and ZSM-5/SBA-15 polymer nanocomposites as a potential tool to overcome MDR in cancer cells. Eur J Pharm Biopharm 142:460–72.

Priya DK, Fang H, Ramya DD, et al. (2021). pH-sensitive chitosan nanoparticles loaded with doxultragrav as milk and food admixtures for paclitaxel anti-HIV therapy. Carbohydr Polym 256:117440.

Ren X, Wang N, Zhou Y. (2021). An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomater 124:179–90.

Singh MS, Tammam SN, Shetab BM, et al. (2017). MDR in cancer: addressing the underlying cellular alterations with the use of nanocarriers. Pharmacol Res 126:2–30.

Tao R, Wang C, Lu Y, et al. (2020). Characterization and cytotoxicity of polypropenol lipid and vitamin E-TPGS hybrid nanoparticles for betulinic acid and low-substituted hydroxyl fullerenol in MHCC97H and L02 cells. Int J Nanomed 15:2733–49.

Tian H, Zhang M, Jin G, et al. (2021). Cu-MOF chemodynamic nanoplatform via modulating glutathione and H2O2 in tumor microenvironment for amplified cancer therapy. J Colloid Interface Sci 587:358–66.

Tian Y, Li JC, Zhu JX, et al. (2017). Folic acid-targeted etoposide cubosomes for theranostic application of cancer cell imaging and therapy. Med Sci Monit 23:2426–35.

Tirella A, Kloc-Muniak K, Good L, et al. (2019). CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment. Int J Pharm 561:114–23.

Trujillo-Nolasco RM, Morales-Avila E, Ocampo-Garcia BE, et al. (2019). Preparation and in vitro evaluation of radioabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Mater Sci Eng C Mater Biol Appl 102:30.

Wan F, Bohr SS-R, Klodzinska SN, et al. (2020). Ultrasmall TPGS-PLGA hybrid nanoparticles for site-specific delivery of antibiotics into Pseudomonas aeruginosa biofilms in lungs. ACS Appl Mater Interfaces 12:380–90.

Wang YY, Zhang DD, Kong YY, et al. (2016). CS/PAATPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells. Colloids Surf B Biointerf 142:358–66.
Xu C, Xu J, Zheng Y, et al. (2020). Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer. J Mater Chem B 8:2726–37.

Yao Q, Liu Y, Kou L, et al. (2019). Tumor-targeted drug delivery and sensitization by MMP2-responsive polymeric micelles. Nanomedicine 19:71–80.

Zhang J, Wang N, Li Q, et al. (2021). A two-pronged photodynamic nanodrug to prevent metastasis of basal-like breast cancer. Chem Commun (Camb) 57:2305–8.

Zhou Y, Ren X, Hou Z, et al. (2021). Engineering a photosensitizer nano-platform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Nanoscale Horiz 6:120–31.